JNJ

226.41

-0.51%↓

ABT

92.88

+1.83%↑

MDT

83.46

+0.1%↑

116.1

+0.6%↑

VEEV

162.02

+0.73%↑

JNJ

226.41

-0.51%↓

ABT

92.88

+1.83%↑

MDT

83.46

+0.1%↑

116.1

+0.6%↑

VEEV

162.02

+0.73%↑

JNJ

226.41

-0.51%↓

ABT

92.88

+1.83%↑

MDT

83.46

+0.1%↑

116.1

+0.6%↑

VEEV

162.02

+0.73%↑

JNJ

226.41

-0.51%↓

ABT

92.88

+1.83%↑

MDT

83.46

+0.1%↑

116.1

+0.6%↑

VEEV

162.02

+0.73%↑

JNJ

226.41

-0.51%↓

ABT

92.88

+1.83%↑

MDT

83.46

+0.1%↑

116.1

+0.6%↑

VEEV

162.02

+0.73%↑

Strona główna・Stock List・AnaptysBio Inc

AnaptysBio Inc

Closed

SectorHealthcare

58.34 14.1

Buy Sell

Overview

Share price change

24h

Current

Min

51.47

Max

60.19

Key metrics
By Trading Economics
Income	35M 50M
Sales	32M 108M
Profit margin	45.833
Employees	104
EBITDA	29M 68M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+32.13% upside

Dividends
By Dow Jones
Next Earnings	1 maj 2026

Market Stats
By TradingEconomics
Market Cap	580M 2.1B
Previous open	44.24
Previous close	58.34

News Sentiment

By Acuity

34%

66%

76 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

19.25 / 21.135 Support & Resistance

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

26 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

26 kwi 2026, 21:14 UTC

Major News Events

Week Ahead for FX, Bonds: Major Central Bank -2-

24 kwi 2026, 19:19 UTC

Acquisitions, Mergers, Takeovers

Intertek Group Rejects EQT's Revised Offer

26 kwi 2026, 23:48 UTC

Market Talk

Nikkei May Rise After U.S. Tech Gains -- Market Talk

26 kwi 2026, 23:44 UTC

Earnings

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

26 kwi 2026, 23:44 UTC

Earnings

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

26 kwi 2026, 23:36 UTC

Market Talk

Major News Events

Gold Falls Amid Dollar's Strength -- Market Talk

26 kwi 2026, 23:33 UTC

Market Talk

Major News Events

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

26 kwi 2026, 05:12 UTC

Earnings

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

24 kwi 2026, 23:37 UTC

Acquisitions, Mergers, Takeovers

Scoring the Cook Era -- Barrons.com

24 kwi 2026, 20:51 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Financial Services Roundup: Market Talk

24 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

24 kwi 2026, 20:39 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 20:09 UTC

Earnings

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 kwi 2026, 19:48 UTC

Market Talk

Major News Events

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 kwi 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 kwi 2026, 19:25 UTC

Acquisitions, Mergers, Takeovers

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 kwi 2026, 19:22 UTC

Earnings

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 kwi 2026, 19:06 UTC

Earnings

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 kwi 2026, 19:05 UTC

Market Talk

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 kwi 2026, 18:30 UTC

Acquisitions, Mergers, Takeovers

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 kwi 2026, 18:28 UTC

Acquisitions, Mergers, Takeovers

Intertek Rejects Revised EQT Offer

24 kwi 2026, 18:12 UTC

Market Talk

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 kwi 2026, 18:06 UTC

Market Talk

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 kwi 2026, 17:42 UTC

Earnings

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 kwi 2026, 17:28 UTC

Earnings

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

32.13% upside

12 Months Forecast

Average 77.8 USD 32.13%

High 140 USD

Low 50 USD

Based on 10 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to AnaptysBio Inc - Dist in the past 3 months.

Technical Score

By Trading Central

19.25 / 21.135Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

76 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.